Study continues; company will begin discussions to transition management of the Anti-amyloid Treatment in Asymptomatic Alzheimer's disease (A4) secondary prevention clinical trial to a new organization
Lilly to End Contract with the University of California, San Diego for A4 Alzheimer's Study (NYSE:LLY)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.